Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema.
CONCLUSION: This case describes a relatively young patient with a poor prognosis but with a remarkable and long-term response to crizotinib monotherapy.
PMID: 31023173 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Genetics | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | PET Scan | Smokers | Thoracostomy | Translocation